{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:18Z","timestamp":1767916818740,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00520-021-06100-4","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T23:02:33Z","timestamp":1614294153000},"page":"4185-4186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points"],"prefix":"10.1007","volume":"29","author":[{"given":"Maura","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-5874","authenticated-orcid":false,"given":"Marco","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"6100_CR1","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1007\/s00520-020-05357-5","volume":"28","author":"I Diel","year":"2020","unstructured":"Diel I, Ansorge S, Hohmann D et al (2020) Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany. Support Care Cancer 28:5223\u20135233 https:\/\/doi-org.bvsp.idm.oclc.org\/10.1007\/s00520-020-05357-5","journal-title":"Support Care Cancer"},{"key":"6100_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","volume":"73","author":"T Loyson","year":"2018","unstructured":"Loyson T, Van Cann T, Schoffski P et al (2018) Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg 73:100\u2013109. https:\/\/doi.org\/10.1080\/17843286.2017.1348001","journal-title":"Acta Clin Belg"},{"key":"6100_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.01","volume":"125","author":"T Higuchi","year":"2018","unstructured":"Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A (2018) Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547\u2013551. https:\/\/doi.org\/10.1016\/j.oooo.2018.02.01","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6100_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.oooo.2017.09.014","volume":"125","author":"N Yarom","year":"2018","unstructured":"Yarom N, Lazarovici TS, Whitefield S et al (2018) Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 125:27\u201330. https:\/\/doi.org\/10.1016\/j.oooo.2017.09.014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6100_CR5","doi-asserted-by":"crossref","unstructured":"Srivastava A, Nogueras Gonzalez GM, Geng Y et al (2020) Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer https:\/\/doi-org.bvsp.idm.oclc.org\/10.1007\/s00520-020-05882-3","DOI":"10.1007\/s00520-020-05882-3"},{"key":"6100_CR6","doi-asserted-by":"crossref","unstructured":"Fusco V, Cabras M, Erovigni F et al (2020) A multicenter observational study on medication-related osteonecrosis of the jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Med Oral Patol Oral Cir Bucal:24318 https:\/\/doi-org.bvsp.idm.oclc.org\/10.4317\/medoral.24318","DOI":"10.4317\/medoral.24318"},{"key":"6100_CR7","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00520-019-04988-7","volume":"28","author":"F Haslbauer","year":"2020","unstructured":"Haslbauer F, Petzer A, Safanda M et al (2020) Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis. Support Care Cancer 28:1855\u20131865 https:\/\/doi-org.bvsp.idm.oclc.org\/10.1007\/s00520-019-04988-7","journal-title":"Support Care Cancer"},{"key":"6100_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","volume":"23","author":"F Saad","year":"2012","unstructured":"Saad F, Brown JE, Poznak CV et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341\u20131347. https:\/\/doi.org\/10.1093\/annonc\/mdr435","journal-title":"Ann Oncol"},{"key":"6100_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00520-015-2904-5","volume":"24","author":"AT Stopeck","year":"2015","unstructured":"Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Mart\u00edn M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 24:447\u2013455. https:\/\/doi.org\/10.1007\/s00520-015-2904-5","journal-title":"Support Care Cancer"},{"key":"6100_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00520-016-3147-9","volume":"25","author":"V Fusco","year":"2017","unstructured":"Fusco V, Bedogni A, Addeo A, Campisi G (2017) Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study? Support Care Cancer 25:345\u2013349. https:\/\/doi.org\/10.1007\/s00520-016-3147-9","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06100-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06100-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T03:36:05Z","timestamp":1624851365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06100-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["6100"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06100-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>Financial interests:<\/b>Dr. Rossi received travel grants from AAA\/Novartis.Dr. Fusco received travel grants from Kyowa Kirin and Celgene.Dr. Gambino received a grant by North-Western Italy Cancer Network (\u201cRete Oncologica Piemonte e Valle d\u2019Aosta\u201d).<b>Non-financial interests:<\/b>Dr. Rossi has served on advisory board (AAA\/ Novartis, Ipsen).Dr. Fusco has served on advisory boards (Amgen. Merck, Servier), transferring the fees to advocacy patient groups.Dr. Cabras and Dr. Alessio declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}